Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation

Patient Preference and Adherence

Volumn 6, Issue , 2012, Pages 521-532

  Matza, Louis S ^a   Phillips, Glenn A ^b   Revicki, Dennis A ^a   Ascher Svanum, Haya ^b   Malley, Karen G ^c   Palsgrove, Andrew C ^a   Faries, Douglas E ^b   Stauffer, Virginia ^b   Kinon, Bruce J ^b   Awad, A George ^d   Keefe, Richard S E ^e   Naber, Dieter ^f  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c University of Toronto ^*

^d UNIVERSITY OF TORONTO   (Canada)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Antipsychotic; Discontinuation; Instrument development; Patient reported outcomes; Schizophrenia; Treatment continuation

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PROCHLORPERAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; ZIPRASIDONE;

ADULT; ADVERSE OUTCOME; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PATIENT ATTITUDE; PERCEPTION; POSITIVE AND NEGATIVE SYNDROME SCALE; REASONS FOR ANTIPSYCHOTIC DISCONTINUATION INTERVIEW; RELIABILITY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; SEMI STRUCTURED INTERVIEW; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; VALIDITY;

EID: 84886039081     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S25635     Document Type: Article

References (25)

1. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085-1097.
2. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223.
3. Weiden PJ. Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial. J Clin Psychiatry. 2007;68 Suppl 1:12-19.
4. Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry. 2006;6:8.
5. Davis SM, Koch GG, Davis CE, LaVange LM. Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies. Schizophr Bull. 2003;29(1):73-80.
6. Dunayevich E, Ascher-Svanum H, Zhao F, et al. Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. J Clin Psychiatry. 2007;68(8):1163-1171.
7. Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull. 2003;29(1):15-31.
8. Weiden PJ, Ross R. Why do patients stop their antipsychotic medications? A guide for families and friends. J Psychiatr Pract. 2002;8(6):413-416.
9. Matza LS, Phillips GA, Revicki DA, et al. Development of a clinician questionnaire and patient interview to assess reasons for antipsychotic discontinuation. Psychiatry Res. October 30, 2011;189(3):463-468. Epub June 17, 2011.
10. Matza LS, Phillips GA, Revicki D, et al. Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia. Psychiatry Res. In press.
11. Barbui C, Kikkert M, Mazzi MA, et al. Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence. Psychopathology. 2009;42(5):311-317.
12. Pyne JM, McSweeney J, Kane HS, Harvey S, Bragg L, Fischer E. Agreement between patients with schizophrenia and providers on factors of antipsychotic medication adherence. Psychiatr Serv. 2006;57(8):1170-1178.
13. Bell M, Milstein R, Beam-Goulet J, Lysaker P, Cicchetti D. The Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale: Reliability, comparability, and predictive validity. Journal Nerv Ment Dis. 1992;180(11):723-728.
14. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276.
15. Haro JM, Kamath SA, Ochoa S, et al. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl. 2003(416):16-23.
16. Cohen J. Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull. 1968;70(4):213-220.
17. Hays RD, Revicki D, Coyne KS. Application of structural equation modeling to health outcomes research. Eval Health Prof. 2005;28(3):295-309.
18. Altman DG. Practical Statistics for Medical Research. London: Chapman & Hall; 1991.
19. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
20. Landis JR, Koch GG. An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics. 1977;33(2):363-374.
21. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean? Schizophr Res. 2005;79(2-3):231-238.
22. Ascher-Svanum H, Nyhuis AW, Stauffer V, et al. Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives. Curr Med Res Opin. 2010;26(10):2403-2410.
23. Kinon BJ, Ascher-Svanum H, Adams DH, Chen L. The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials. J Clin Psychopharmacol. 2008;28(5):544-549.
24. Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med. 2005;3:21.
25. Liu-Seifert H, Adams DH, Ascher-Svanum H, Faries DE, Kinon BJ. Patient perception of medication benefit and early treatment discontinuation in a 1-year study of patients with schizophrenia. Patient Prefer Adherence. 2007;1:9-17.